We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-22.55%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$194M
AUM Growth
+$14.4M
(+8%)
Cap. Flow
+$69.7M
Cap. Flow
% of AUM
35.98%
Top 10 Holdings %
Top 10 Hldgs %
60.4%
Holding
41
New
9
Increased
19
Reduced
7
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$13.4M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$10.6M |
| 3 |
Cigna
CI
|
+$9.19M |
| 4 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$6.37M |
| 5 |
EFOR
Everforth Inc
EFOR
|
+$5.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PVLA
Palvella Therapeutics
PVLA
|
+$5.15M |
| 2 |
MacroGenics
MGNX
|
+$4.42M |
| 3 |
SHPG
Shire pic
SHPG
|
+$4.24M |
| 4 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
+$4.1M |
| 5 |
Indaptus Therapeutics
INDP
|
+$4.02M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.94% |
| 2 | Technology | 2.47% |
| 3 | Financials | 0.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Evolus
EOLS
$587M
| $2.33M | 1.2% |
195,911
+57,451
| +41% | +$819K |
|
27
Tempest Therapeutics
TPST
$17.5M
| $2.04M | 1.05% |
1,317
+794
| +152% | +$1.63M |
|
28
Ligand Pharmaceuticals
LGND
$5.59B
| $1.71M | 0.88% |
+20,198
| New | +$2.15M |
|
|
GTS
29
DELISTED
Triple-S Management Corporation
GTS
| $1.14M | 0.59% |
+68,863
| New | +$1.19M |
|
|
CLVS
30
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.08M | 0.56% |
+60,100
| New | +$1.23M |
|
31
Avalo Therapeutics
AVTX
$1.05B
| $994K | 0.51% |
+107
| New | +$1.19M |
|
|
PVLA
32
Palvella Therapeutics
PVLA
$2.16B
| $885K | 0.46% |
4,161
-16,613
| -80% | -$5.15M |
|
|
OPTN
33
DELISTED
OptiNose
OPTN
| $870K | 0.45% |
+9,354
| New | +$1.34M |
|
|
CDTX
34
DELISTED
Cidara Therapeutics
CDTX
| $578K | 0.3% |
12,288
-3,957
| -24% | -$282K |
|
35
Neurogene
NGNE
$732M
| $173K | 0.09% |
4,014
+1,181
| +42% | +$57.5K |
|
|
KZR
36
DELISTED
Kezar Life Sciences
KZR
| – | – |
-5,233
| Closed | -$1.12M |
|
37
MeiraGTx Holdings
MGTX
$1.33B
| – | – |
-38,746
| Closed | -$527K |
|
38
PUT
Travere Therapeutics
TVTX
$6.19B
| – | – |
-102,300
| Closed | -$2.94M |
|
|
EIGR
39
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| – | – |
-11,382
| Closed | -$4.1M |
|
|
NVLN
40
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| – | – |
-444,068
| Closed | -$1.31M |
|
|
SHPG
41
DELISTED
Shire pic
SHPG
| – | – |
-23,400
| Closed | -$4.24M |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q4 2018 Portfolio in Review
As of Q4 2018, Prosight Management held 41 positions worth $194M, up 8% from $179M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Prosight Management deployed $69.7M of net new capital in Q4 2018, opening 9 new positions and adding to 19 existing holdings. Its largest new stake was Wellcare Health Plans, Inc.: 50,000 shares worth $11.8M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Palvella Therapeutics, an estimated $5.15M trimmed.
- Prosight Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 50,000 shares worth $11.8M.
- Prosight Management added most to Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018, an estimated $10.6M increase.
- Prosight Management's biggest Q4 2018 reduction was Palvella Therapeutics, cutting an estimated $5.15M.
- Prosight Management fully exited Shire pic in Q4 2018, selling an estimated $4.24M.
- Prosight Management's ten largest holdings make up 60% of its $194M portfolio in Q4 2018.
- Prosight Management opened 9 new positions and closed 6 in Q4 2018.
- Prosight Management's portfolio value rose 8% quarter-over-quarter to $194M.
Based on Prosight Management's 13F filing for Q4 2018, filed 14 Feb 2019.